Neutralization assays measure the ability of an antibody to block a biological function — typically the ability of a virus to infect cells, a ligand to bind its receptor, or a cytokine to activate a signaling pathway. Unlike standard binding assays (ELISA, WB), neutralization assays provide functional evidence that an antibody not only binds its target but actively inhibits its biological activity.
This makes neutralization assays essential tools in infectious disease research, immuno-oncology, vaccine development, and therapeutic antibody characterization. This guide covers the most common formats, provides a step-by-step pseudovirus neutralization protocol, and offers practical advice for selecting antibodies and optimizing your assay.
In This Guide
1. What Does Neutralization Mean?
2. Common Neutralization Assay Formats
3. Step-by-Step: Pseudovirus Neutralization Assay Protocol
4. Step-by-Step: Receptor-Blocking ELISA (sVNT) Protocol
5. Antibody Selection for Neutralization Studies
6. Optimizing Dose-Response Curves
7. Troubleshooting Neutralization Assays
8. Frequently Asked Questions
1. What Does Neutralization Mean?
In immunology, neutralization refers to the ability of an antibody to abolish or reduce the biological activity of its target molecule. The antibody achieves this by binding to a functionally critical site on the target — for example, the receptor-binding domain (RBD) of a viral spike protein, the active site of a toxin, or the receptor-binding interface of a cytokine — physically preventing the target from engaging its natural binding partner.
Not all antibodies that bind a target can neutralize it. An antibody may bind a non-functional epitope (e.g., a region on the viral capsid distant from the receptor-binding site), providing excellent ELISA or WB signal but no functional blocking. This is why neutralization must be tested with a functional assay, not inferred from binding data alone. For more on the distinction between binding specificity and functional activity, see our Antibody Specificity and Validation guide.
Key distinction: A neutralizing antibody blocks biological function (viral infection, receptor signaling, enzymatic activity). A non-neutralizing antibody binds the same target but at a region not involved in function — still useful for detection (ELISA, WB, IHC, flow cytometry) and may contribute to Fc-mediated effector functions (in vivo ADCC, phagocytosis), but cannot directly inhibit the target’s activity.
2. Common Neutralization Assay Formats
The choice of neutralization assay format depends on your target (virus, cytokine, toxin), required biosafety level, throughput needs, and whether you need a cell-based readout or a biochemical endpoint.
| Format |
Principle |
Best For |
Biosafety |
| PRNT (Plaque Reduction Neutralization Test) |
Antibody + live virus incubated together, then added to cell monolayer. Plaques counted; reduction indicates neutralization. |
Gold standard for virus neutralization; vaccine efficacy studies |
BSL-2 or BSL-3 |
| Pseudovirus Neutralization |
Pseudotyped virus (lentivirus or VSV backbone + target glycoprotein + reporter gene). Neutralizing antibody reduces reporter signal. |
High-throughput screening; BSL-3 virus surrogates (SARS-CoV-2, Ebola); vaccine nAb measurement |
BSL-2 (replication-incompetent) |
| Cell-Based Reporter Assay |
Target cells express reporter gene under pathway control. Neutralizing antibody blocks activation, reducing reporter signal. |
Cytokine/receptor blocking (e.g., anti-PD-1 blocking PD-1/PD-L1); checkpoint inhibitor characterization |
BSL-1/BSL-2 |
| Receptor-Blocking ELISA (sVNT) |
Plate coated with receptor; labeled ligand added ± antibody. Blocking reduces signal. See our ELISA Protocol Guide. |
Quick functional screening; surrogate virus neutralization test (sVNT) for SARS-CoV-2 |
BSL-1 (no live virus) |
| CPE Inhibition |
Live virus + antibody added to cells. Cell death (CPE) scored visually or by viability assay. Neutralizing antibody protects cells. |
Classical virology; broadly applicable to cytopathic viruses |
BSL-2 or BSL-3 |
Choosing a format: For viral neutralization, the pseudovirus assay offers the best balance of biological relevance and safety. For receptor-ligand blocking in immuno-oncology (e.g., PD-1/PD-L1, CTLA-4), cell-based reporter assays are standard. For high-throughput initial screening, receptor-blocking ELISA is fastest but least physiologically representative.
3. Step-by-Step: Pseudovirus Neutralization Assay Protocol
The pseudovirus neutralization assay is the most widely used format for measuring neutralizing antibody activity against viral targets without requiring BSL-3 containment. The protocol below uses a luciferase-reporter pseudovirus (VSV or lentivirus backbone) and can be adapted for any pseudotyped glycoprotein.
Materials Required
| Item |
Specification |
| Pseudovirus stock |
VSV-ΔG or lentivirus pseudotyped with target glycoprotein, luciferase reporter. Titer: ≥106 RLU/mL. |
| Target cells |
Cells expressing viral receptor (e.g., HEK293T-ACE2 for SARS-CoV-2, MDCK for influenza). Passage ≤20. |
| Test antibody |
Purified, endotoxin-free, carrier-free. Stock concentration known (by A280 or BCA). |
| Isotype control antibody |
Same species/isotype as test antibody. Confirms specificity of neutralization. |
| Luciferase substrate |
Bright-Glo, ONE-Glo, or equivalent lytic luciferase reagent. |
| Plates |
96-well white opaque flat-bottom (for luminescence); tissue culture-treated. |
| Medium |
DMEM + 10% FBS + 1% Pen/Strep (or medium appropriate for your target cell line). |
Procedure
Day 0 — Seed Target Cells
1. Trypsinize target cells and resuspend at 1 × 105 cells/mL in complete medium.
2. Seed 100 μL per well (10,000 cells/well) in a 96-well plate.
3. Incubate overnight at 37°C, 5% CO2 to allow cell attachment (≥80% confluence next day).
Day 1 — Prepare Antibody-Virus Mixture
4. Prepare an 8-point, 4-fold serial dilution of the test antibody in serum-free medium (starting concentration: 50 μg/mL → 12.5 → 3.125 → 0.781 → 0.195 → 0.049 → 0.012 → 0.003 μg/mL). For guidance on serial dilutions, see our Antibody Dilution Optimization guide.
5. Prepare the same dilution series for the isotype control antibody (highest concentration only is acceptable as a single-point control).
6. Dilute pseudovirus stock in serum-free medium to a working titer that produces ~105–106 RLU in the virus-only control (typically 50–200 × TCID50/well, or MOI 0.1–0.5).
7. Mix equal volumes (50 μL + 50 μL) of each antibody dilution with the diluted pseudovirus in a separate round-bottom 96-well plate. Include virus-only wells (50 μL medium + 50 μL virus) and cell-only wells (100 μL medium, no virus).
8. Incubate the antibody-virus mixture for 1 h at 37°C to allow antibody-antigen binding to reach equilibrium.
Day 1 — Infect Cells
9. Remove culture medium from the pre-seeded target cell plate (Day 0).
10. Transfer 100 μL of the antibody-virus mixture from each well to the corresponding well of the target cell plate.
11. Centrifuge the plate briefly (300 × g, 5 min, optional) to facilitate virus-cell contact.
12. Incubate for 48–72 h at 37°C, 5% CO2. For lentiviral pseudoviruses, 48 h is typical; for VSV-based pseudoviruses, 24 h may be sufficient.
Day 3 (or Day 2) — Read and Analyze
13. Remove medium from wells. Add 50 μL of luciferase substrate per well.
14. Incubate 5–10 min at room temperature in the dark.
15. Read luminescence (RLU) on a plate reader.
16. Calculate % neutralization for each antibody concentration:
% Neutralization = [1 − (RLUsample − RLUcell-only) / (RLUvirus-only − RLUcell-only)] × 100
17. Plot % neutralization vs. antibody concentration (log scale). Fit a 4-parameter logistic (4PL) regression curve (GraphPad Prism, R, or Python scipy). Derive IC50 from the midpoint.
Plate Layout Recommendation (96-well)
Columns 1–8: test antibody serial dilution (rows A–C = triplicate). Columns 9–10: isotype control (highest concentration, triplicate). Column 11: virus-only (0% neutralization control). Column 12: cell-only (background). This layout gives you triplicate data at every concentration plus all necessary controls in a single plate.
4. Step-by-Step: Receptor-Blocking ELISA (sVNT) Protocol
The surrogate virus neutralization test (sVNT) is a competitive ELISA that measures antibody-mediated blocking of a viral protein–receptor interaction without any live virus or cell culture. This makes it the simplest neutralization format, suitable for BSL-1 labs and high-throughput seroprevalence screening.
Step 1 — Coat the plate. Coat a 96-well ELISA plate with the receptor protein (e.g., recombinant human ACE2, 2 μg/mL in PBS, 100 μL/well). Incubate overnight at 4°C. Wash 3× with PBST (PBS + 0.05% Tween-20). Block with 2% BSA in PBS for 1 h at 37°C. Wash 3×. For detailed coating optimization, see our ELISA Protocol Guide.
Step 2 — Pre-incubate antibody + labeled ligand. In a separate plate, mix test antibody serial dilutions (8-point, 3-fold) with a fixed concentration of HRP-conjugated viral protein (e.g., HRP-RBD, at a concentration that gives OD ~1.0–1.5 without antibody). Incubate 30 min at 37°C.
Step 3 — Add mixture to coated plate. Transfer 100 μL of the antibody-HRP-ligand mixture to the receptor-coated wells. Incubate 30 min at 37°C. Wash 4× with PBST.
Step 4 — Develop and read. Add 100 μL TMB substrate. Develop 10–15 min in the dark. Stop with 50 μL 2M H2SO4. Read OD450.
Step 5 — Calculate % inhibition.
% Inhibition = [1 − (ODsample / ODno-antibody control)] × 100
An inhibition rate ≥30% is generally considered positive for neutralizing activity. Fit 4PL to determine IC50.
5. Antibody Selection for Neutralization Studies
Not every antibody against a target will neutralize. When selecting antibodies for neutralization experiments, consider:
| Factor |
Guidance |
| Epitope location |
The antibody must bind a functionally critical region: RBD for viral entry, active site for enzymes, receptor-binding interface for cytokines. Antibodies targeting non-functional epitopes will not neutralize regardless of affinity. |
| Application validation |
Look for antibodies explicitly listed as “Neutralization” or “Functional assay” validated on the product datasheet. “ELISA-validated” alone does not imply neutralization capability. |
| Clonality |
Monoclonal antibodies are strongly preferred because they target a single, defined epitope, enabling precise functional epitope mapping and reproducible dose-response behavior. |
| Format and purity |
For cell-based and in vivo neutralization, use endotoxin-free, azide-free antibody. Carrier-free (no BSA) is preferred. Recombinant antibodies offer batch-to-batch consistency critical for reproducible IC50 curves. For in vivo studies, see our InVivo antibody collection. |
| Isotype |
For in vivo neutralization, human IgG1 or IgG4 (or mouse equivalents). IgG4 is preferred for pure blocking (no Fc effector function); IgG1 engages ADCC/CDC for cell-killing applications. Isotype controls are essential for confirming specificity. |
| Size and epitope access |
VHH nanobodies (~15 kDa) can access cryptic epitopes (receptor-binding pockets, viral canyon regions) that conventional IgG (~150 kDa) cannot reach. |
6. Optimizing Dose-Response Curves
Neutralization assays are quantitative: the goal is to determine the IC50 (antibody concentration that inhibits 50% of activity) or NT50 (serum dilution that reduces infection by 50%). Proper optimization is critical for reproducibility.
1. Use a wide concentration range. Start with at least an 8-point, 3- or 4-fold serial dilution spanning 3–4 logs (e.g., 50 μg/mL down to 0.003 μg/mL). This ensures you capture the full sigmoidal curve from 0% to 100% inhibition.
2. Include proper controls. Virus/ligand-only (0% inhibition baseline), cells-only (background/maximum viability), and isotype control antibody at the highest concentration (confirms target specificity).
3. Pre-incubate antibody with target. For virus neutralization, incubate the antibody-virus mixture for 1 h at 37°C. For receptor-blocking ELISA, pre-incubate antibody with soluble ligand before adding to the coated receptor plate.
4. Run in triplicate. Biological variability in cell-based assays demands replicates. Report IC50 with 95% confidence intervals.
5. Fit the curve properly. Use a 4-parameter logistic (4PL) regression. Most graphing software (GraphPad Prism, R, Python) supports 4PL natively. IC50 is derived from the midpoint of the fitted curve.
To complement IC50 data with binding kinetics (on-rate, off-rate, KD), label-free methods such as SPR and BLI provide mechanistic insight into why certain antibodies neutralize more potently.
7. Troubleshooting Neutralization Assays
| Problem |
Possible Causes |
Solutions |
| No neutralization at any concentration |
Antibody binds a non-functional epitope; wrong target species; antibody denatured or aggregated |
Confirm antibody binds the receptor-binding domain by competition ELISA. Check species cross-reactivity on the datasheet. Run SDS-PAGE / SEC to check antibody integrity. Try a different clone known to bind the functional epitope. |
| Curve plateaus below 100% inhibition |
Virus uses alternative entry pathways; antibody only partially occludes the receptor-binding interface; antibody-resistant variants present |
Report maximum inhibition (%) alongside IC50. Consider combining antibodies targeting different epitopes for synergistic neutralization. For viruses, sequence the stock to check for escape mutants. |
| High variability between replicates |
Inconsistent cell seeding; pipetting errors in serial dilution; uneven plate incubation (edge effects) |
Use multichannel pipettes for serial dilution. Count cells with a hemocytometer or automated counter before seeding. Avoid using outer wells (fill with PBS for humidity control). Ensure plate reader integration time is adequate (≥0.5 s/well). |
| High background in cell-only control |
Luciferase substrate auto-luminescence; media interference; cells not fully washed |
Ensure substrate is fresh (check expiry). Remove all medium before adding substrate. Add an extra wash step. Use white opaque plates to minimize well-to-well cross-talk. |
| Very low signal in virus-only control |
Pseudovirus titer too low; cells not expressing receptor; cells over-confluent (reduced receptor exposure) |
Titer pseudovirus stock and use an amount that gives 105–106 RLU. Confirm receptor expression by flow cytometry. Seed cells at 50–70% confluence (not 100%). |
| Isotype control also shows inhibition |
Non-specific Fc-mediated blocking; endotoxin contamination in antibody prep; steric hindrance from high IgG concentrations |
Use endotoxin-tested, carrier-free antibody. Reduce starting concentration. If isotype inhibition >20% at top dose, lower the maximum antibody concentration. This is a genuine specificity issue that must be resolved before interpreting test antibody data. |
| Prozone effect (decreased neutralization at highest concentrations) |
Antibody excess causes antigen-antibody complex aggregation that enhances uptake; bispecific/multivalent interactions at very high concentrations |
Extend the dilution series with additional lower points. If prozone persists, report IC50 from the ascending portion of the curve only. Some antibodies genuinely show prozone effects; document and note in your report. |
8. Frequently Asked Questions
What is the difference between a neutralizing and a non-neutralizing antibody?
Both bind the target antigen, but only a neutralizing antibody blocks the target’s biological function. A non-neutralizing antibody binds a region not involved in receptor binding or enzymatic activity. Non-neutralizing antibodies are still useful for detection (ELISA, WB, IHC, flow cytometry) and may contribute to Fc-mediated immune responses (in vivo ADCC, phagocytosis), but cannot directly inhibit the target’s function.
Can I use a polyclonal antibody for neutralization?
Yes. Polyclonal sera (convalescent serum, post-vaccination serum) are routinely tested in viral neutralization assays to assess the overall neutralizing response. However, the IC50 reflects the combined activity of the mixture, not a single molecular species. For mechanistic studies or epitope-level analysis, monoclonal antibodies are preferred.
What is a surrogate virus neutralization test (sVNT)?
The sVNT is a competitive ELISA-based assay measuring antibody-mediated blocking of a viral protein–receptor interaction (e.g., SARS-CoV-2 RBD–ACE2) in a plate-based format. It requires no live virus, pseudovirus, or cell culture, making it the simplest and fastest neutralization format. sVNTs correlate well with PRNT and pseudovirus assays and are widely used for seroprevalence screening and vaccine monitoring. See the step-by-step sVNT protocol in Section 4 above.
How do I distinguish between steric blocking and allosteric inhibition?
Steric blocking occurs when the antibody physically occupies the receptor-binding site. Allosteric inhibition occurs when the antibody binds a distant site but induces a conformational change reducing activity. Competitive binding assays primarily detect steric blocking. To distinguish mechanisms, epitope mapping (mutagenesis or HDX-MS) combined with structural studies (cryo-EM, X-ray crystallography) is typically required.
What is a good IC₅₀ for a neutralizing antibody?
It depends on context. Therapeutic candidates typically have IC50 values in the low nanomolar range (1–100 ng/mL). Research-grade neutralizing antibodies used as positive controls are acceptable at 1–10 μg/mL. Research biosimilar antibodies are commonly used as reference standards. Always compare IC50 values under identical assay conditions, as they vary significantly between formats, cell lines, and virus strains.
What is the difference between IC₅₀ and NT₅₀?
IC50 (Inhibitory Concentration 50%) is the antibody concentration that blocks 50% of biological activity — used when testing purified monoclonal antibodies at known concentrations. NT50 (Neutralization Titer 50%) is the serum dilution factor that reduces infection by 50% — used when testing polyclonal serum samples (post-vaccination, convalescent sera) where the exact antibody concentration is unknown. Both are derived from the midpoint of a 4PL-fitted dose-response curve.
Can I use neutralization assays for checkpoint inhibitor characterization?
Yes. PD-1/PD-L1 and CTLA-4/B7 blocking assays are neutralization assays by definition — they measure the ability of an antibody to block a receptor-ligand interaction. Cell-based reporter assays (PD-1/PD-L1 Jurkat-NFAT-Luc) are the standard for checkpoint inhibitor potency testing and biosimilar comparability studies.
How many replicates do I need, and how should I report results?
A minimum of technical triplicates per concentration is standard. For publication-quality data, perform 3 independent biological replicates (separate experiments on different days). Report the geometric mean IC50 with 95% confidence interval. Include the Hill slope from the 4PL fit, as a slope significantly different from −1 may indicate cooperative binding or assay artifacts. Always show representative dose-response curves alongside the IC50 table.
Neutralizing Antibodies from abinScience
abinScience offers over 810 antibodies validated for neutralization, spanning viral targets (SARS-CoV-2, RSV, influenza, Ebola), immune checkpoint proteins (PD-1, PD-L1, CTLA-4), and cytokines. Available in human IgG, mouse IgG, and VHH/nanobody formats. All products include functional validation data and lot-specific CoA.
Browse Neutralizing Antibodies → Browse Biosimilar Reference Standards →
References
1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8
2. Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680-686. doi: 10.1080/22221751.2020.1743767
3. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z
4. Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1):4059. doi: 10.1038/s41467-020-17892-0
From Binding to Blocking: Functional Antibodies
810+ neutralizing antibodies for virology, immuno-oncology, and cytokine research. Functionally validated with dose-response data.
Explore Neutralizing Antibodies →
This article is provided for educational purposes only. For technical support, contact support@abinscience.com.
中文
English
한국어
日本語
Español
Français
Русский
